4:50 PM
 | 
Jun 18, 2018
 |  BC Extra  |  Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing. Ziopharm was down $0.79 (18%) to $3.51 on Monday.

The therapy, produced using Ziopharm's Sleeping Beauty non-viral integration technology, comprises CD19-targeted CAR T cells co-expressing membrane-bound...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >